TODAY'S PAPER
55° Good Evening
55° Good Evening
Business

Bradley T. Sheares joins board of Henry Schein Inc.

Melville-based Henry Schein Inc. has elected a new member, Bradley T. Sheares, to its board of directors, the company said Monday.

Schein distributes health care products and services to dental, medical and veterinary offices.

Sheares most recently served as chief executive of Reliant Pharmaceuticals, Inc., leading that company as it was acquired by GlaxoSmithKline plc. in December 2007.

Before heading Reliant he was president of the U.S. human health division of Merck & Co. from 2001-2006, the culmination of a 19-year career with that company. Sheares has served on the boards of Honeywell International, The Progressive Corp., IMS Health and Covance Inc.

"Clearly the medical landscape in the United States and around the world is quickly changing, with health care focusing more closely on disease prevention and wellness," Stanley M. Bergman, chairman and chief executive of Henry Schein, said in a statement. Sheares' "insights into these emerging developments will figure prominently as we position our company to take full advantage of new market opportunities . . ."

Sheares is a former chairman of the National Pharmaceutical Council board of directors. He has a bachelor's degree in chemistry from Fisk University; a doctorate in biochemistry from Purdue University; and completed postdoctoral training as a Lucille P. Markey Scholar and National Institutes of Health Research Fellow at the Massachusetts Institute of Technology.

"It is a pleasure to join this distinguished board and to be part of a company with such a rich history and promising future," Sheares said in the company statement.

"I have been impressed by the organization's resolve to help physicians, dentists and veterinarians navigate this fast-changing health care landscape, as well as the Company's values-based culture and high standards of corporate conduct," Sheares said. "I look forward to joining this strong team that will help Henry Schein continue its remarkable growth for many years to come."

Comments

We're revamping our Comments section. Learn more and share your input.

More news